Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP11 | Q9NR21 | 10/20 | 0.56 |
| ▸ | PARP10 | Q53GL7 | 10/20 | 0.56 |
| ▸ | PRKACA | P17612 | 1/20 | 0.49 |
| ▸ | PRKACG | P22612 | 1/20 | 0.49 |
| ▸ | PRKACB | P22694 | 1/20 | 0.49 |
| ▸ | PARP1 | P09874 | 2/20 | 0.46 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.46 |
| ▸ | GRM5 | P41594 | 7/20 | 0.46 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23136956 | 0.85 | SMYD3 (0.50) | PARP1GRM5GSK3B | |
| SCHEMBL1727165 | 0.83 | PARP11 (0.72) | PARP11PARP10PRKACAPRKACGPRKACB | |
| SCHEMBL30337030 | 0.81 | PARP11 (0.58) | PARP11PARP10PRKACAPRKACGPRKACB | |
| SCHEMBL1417726 | 0.81 | PARP11 (0.58) | PARP11PARP10PRKACAPRKACGPRKACB | |
| SCHEMBL8511891 | 0.80 | KDM4E (0.54) | — | |
| SCHEMBL30421037 | 0.80 | PARP10 (0.57) | PARP11PARP10PRKACAPRKACGPRKACB | |
| SCHEMBL12683051 | 0.79 | PRKACA (0.58) | PARP11PARP10PRKACAPRKACGPRKACB | |
| SCHEMBL30336933 | 0.79 | PRKACA (0.58) | PARP11PARP10PRKACAPRKACGPRKACB | |
| SCHEMBL12810163 | 0.78 | PARP10 (0.54) | PARP11PARP10PRKACAPRKACGPRKACB | |
| SCHEMBL15880055 | 0.77 | CRBN (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117242073-A | PRMT5 inhibitors and uses thereof | 海思科医药集团股份有限公司 | 2023-12-15 | — | — | CN | disclosed |